NCT02123524View on ClinicalTrials.gov

Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions
Symptomatic Superficial Vein Thrombosis
Interventions
DRUG

Rivaroxaban

DRUG

Placebo

Trial Locations (11)

T6G 2B7

University of Alberta Hospital, Edmonton

L8L2X2

Hamilton General Hospital, Hamilton

L8N4A6

St Josephs Healthcare, Hamilton

L8V1C3

Juravinski Hospital, Hamilton

Unknown

McMaster Hospital, Hamilton

Montreal General Hospital, Montreal

St Mary's Hospital, Montreal

K1H8L6

The Ottawa Hospital, Ottawa

H1T 2M4

Hopital Maisonneuve - Rosemount, Montreal

H3T1E2

Jewish General Hospital, Montreal

H4J1C5

Hopital Sacre Coeur, Montreal

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

McMaster University

OTHER